VIVUS (VVUS) Sinks Further on Qsymia Patent Worries
Tweet Send to a Friend
Get Alerts VVUS Hot Sheet
Trade VVUS Now!
Shares of VIVUS, Inc. (Nasdaq: VVUS) are getting pounded for the second straight session after Citron Research raised questions about the patent protection for its recently approved obesity drug Qsymia. After getting slammed 11 percent Thursday, shares are down another 13 percent already today.
Yesterday's Citron report struck a nerve with investors as they compared VIVUS to Nitromed - a biotech company that received FDA approval some 8 years ago, and trading over $20 per share, but then sold some three year later for less than a dollar per share. Citron said it is "astounded by the weakness of Vivus' intellectual property protection."
However, Wall Street analysts are saying 'not to fast.' Rodman & Renshaw's Michael King tried to reassure investors that the company is in fact protected by patents. He reiterated his Market Outperform rating and $52 price target on shares of VIVUS Friday morning.
Shares of VVUS last traded at $22.33, down 13.4 percent.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Yesterday's Citron report struck a nerve with investors as they compared VIVUS to Nitromed - a biotech company that received FDA approval some 8 years ago, and trading over $20 per share, but then sold some three year later for less than a dollar per share. Citron said it is "astounded by the weakness of Vivus' intellectual property protection."
However, Wall Street analysts are saying 'not to fast.' Rodman & Renshaw's Michael King tried to reassure investors that the company is in fact protected by patents. He reiterated his Market Outperform rating and $52 price target on shares of VIVUS Friday morning.
Shares of VVUS last traded at $22.33, down 13.4 percent.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- J.P. Morgan (JPM) CEO Dimon Might Have Enough Votes to Stay Chairman - NY Times
- QVT Financial Purchase $20M of Convertible Debt Issued by VIVUS (VVUS)
- UPDATE: Cell Therapeutics (CTIC) on The Move
Create E-mail Alert Related Categories
FDA, Momentum Movers, Trader Talk, Trading HaltsRelated Entities
Rodman & Renshaw, Citron Research
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
